menu
    • menu

    Company profile for Trevi Therapeutics

    NEW Drugs in Dev: 2
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    We are developing nalbuphine ER to treat serious neurologically mediated conditions by targeting the central and peripheral nervous systems. Nalbuphine ER is an oral, extended-release formulation of nalbuphine, which has a long history of efficacy and safety, having been approved for more than 20 years in the United States and Europe as a subcutaneous injection for relief of moderate to severe pain in the hospital setting. ...
    We are developing nalbuphine ER to treat serious neurologically mediated conditions by targeting the central and peripheral nervous systems. Nalbuphine ER is an oral, extended-release formulation of nalbuphine, which has a long history of efficacy and safety, having been approved for more than 20 years in the United States and Europe as a subcutaneous injection for relief of moderate to severe pain in the hospital setting. Our novel oral formulation is unlocking new market opportunities and the potential to significantly improve the quality of life of patients who currently have few treatment options.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Trevi TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    195 Church Street, 14th Floor New Haven, CT 06510
    Telephone
    Telephone
    (203) 304-2499
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.trevitherapeutics.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/trevi-therapeutics-inc-/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    euroPLX 90 Lisbon

    Not Confirmed

    envelop Contact Supplier

    euroPLX 90 Lisbon

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Trevi Therapeutics Publishes Phase 2B IPF Chronic Cough Trial
    Trevi Therapeutics Publishes Phase 2B IPF Chronic Cough Trial

    22 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/trevi-therapeutics-announces-publication-of-data-from-the-phase-2b-ipf-chronic-cough-trial-of-nalbuphine-er-in-the-journal-of-the-american-medical-association-jama-302668332.html

    PR NEWSWIRE
    22 Jan 2026
    Share Share
    Trevi Pharma Names David Hastings CFO
    Trevi Pharma Names David Hastings CFO

    04 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/trevi-therapeutics-announces-appointment-of-david-hastings-as-chief-financial-officer-302632615.html

    PR NEWSWIRE
    04 Dec 2025
    Share Share
    Trevi Therapeutics Reveals Q3 2025 Financials And Business
    Trevi Therapeutics Reveals Q3 2025 Financials And Business

    13 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/trevi-therapeutics-reports-third-quarter-2025-financial-results-and-provides-business-updates-302614805.html

    PR NEWSWIRE
    13 Nov 2025
    Share Share
    Trevi To Release Q3 2025 Financials & Corporate Update
    Trevi To Release Q3 2025 Financials & Corporate Update

    06 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/trevi-therapeutics-to-report-third-quarter-2025-financial-results-and-provide-a-corporate-update-on-november-13-2025-302607029.html

    PR NEWSWIRE
    06 Nov 2025
    Share Share
    Trevi Therapeutics Joins Stifel 2025 Healthcare Conference
    Trevi Therapeutics Joins Stifel 2025 Healthcare Conference

    04 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/trevi-therapeutics-to-participate-in-stifel-2025-healthcare-conference-302602653.html

    PR NEWSWIRE
    04 Nov 2025
    Share Share
    Trevi Therapeutics Presents Oral Abstracts At CHEST 2025 Meeting
    Trevi Therapeutics Presents Oral Abstracts At CHEST 2025 Meeting

    08 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/trevi-therapeutics-announces-oral-presentation-and-abstracts-at-chest-2025-annual-meeting-302577932.html

    PR NEWSWIRE
    08 Oct 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search